Mishal Mendiratta-Lala, MD

Mishal Mendiratta-Lala
Agree Family Research Professor of Image Guided Intervention
Clinical Professor of Radiology and Medical Director
ACU Northeast Radiology
Medical School
Office:
Michigan Medicine
Radiology
1500 East Medical Center Drive
Ann Arbor, MI 48019
Email:
[email protected]
Available to mentor
Mishal Mendiratta-Lala, MD
Mishal Mendiratta-Lala
Clinical Professor
  • About
  • Center Memberships
  • Research Overview
  • Recent Publications
  • Manage Your Profile

  • About

    Dr. Mishal Mendiratta-Lala earned her B.S. in Health Sciences from Kalamazoo College in 2000. She earned her MD from Wayne State University School of Medicine in 2004. She went on to perform her residency in Diagnostic Radiology at Henry Ford Hospital in Detroit, Michigan. Following this she performed a Fellowship within Abdominal Radiology at Beth Israel Deaconess Hospital at Harvard University in 2009. in 2010 she became a Clinical Assistant Professor of Radiology at Wayne State University School of Medicine and a Senior Staff Physician at Henry Ford Hospital in Detroit, Michigan. She would go on to become a Clinical Assistant Professor within the Department of Radiology at Michigan Medicine in 2015 and later would become an Associate Professor in the Department of Radiology in 2018. She has serves as the Co-Director of Interventional Oncology within the Department of Radiology at the University of Michigan since 2021 as well as the Director of Abdominal MRI within the department of Radiology at the University of Michigan.

    Center Memberships

    • Center Member
      Rogel Cancer Center

    Research Overview

    cross-sectional interventional procedures, interventional oncology, hepatocellular carcinoma diagnosis, staging, and treatment response, histotripsy and locoablative therapy, MR Imaging, hepatobiliary imaging

    Recent Publications

    See All Publications
    • Journal Article
      Histotripsy dose impacts tumor cellular damage and treatment outcomes in a preclinical model of hepatocellular carcinoma
      Worlikar T, Zhang M, Yu M, Kim H, Shi J, Hall TL, Mendiratta-Lala M, Cho CS, Xu Z. Scientific Reports, 2026 Dec 1; 16 (1): DOI:10.1038/s41598-026-48331-7
      PMID: 42034785
    • Journal Article
      Convergence of Local and Systemic Therapies: A Comprehensive Society of Interventional Oncology Framework for 90Y Radioembolization with Immunotherapy in HCC.
      Avritscher R, Kim E, Chew V, Abou-Alfa GK, Kaseb A, Toskich B, Gade T, Mendiratta-Lala M, Krishnan S, Kappadath SC, Salem R. Radiology, 2026 Sep; 320 (3): e251415 DOI:10.1148/radiol.251415
      PMID: 42678260
    • Journal Article
      Histotripsy-Induced Acute Kidney Injury Following Liver Tumor Treatment: A Preliminary Report of 9 Cases
      Poe LL, Kisting AL, Mendiratta-Lala M, Abi-Jaoudeh N, Breuer JA, Fidelman N, Raman SS, Lee FT, Lokken RP, Caoili EM, Shah R, Hinshaw JL. Journal of Vascular and Interventional Radiology, 2026 Sep 1; 37 (9): DOI:10.1016/j.jvir.2026.108882
      PMID: 42218940
    • Journal Article
      Ablative Therapies for Liver Tumors
      Farooq AR, Aslam A, Lala K, Mendiratta-Lala M. Hematology Oncology Clinics of North America, 2026 Aug 1; 40 (4): 573 - 589. DOI:10.1016/j.hoc.2026.05.008
      PMID: 42331686
    • Journal Article
      Retraction : A hybridized channel selection approach with deep convolutional neural network for effective ovarian cancer prediction in periodic acid-Schiff-stained images (Concurrency and Computation: Practice and Experience, (2023), 35, 5, 10.1002/cpe.7568)
      Ramasamy S, Kaliyaperumal V, Sakala MD, Curci NE, Masch WR, Mendiratta-Lala M, Stein EB, Wasnik AP, Sciallis AP, Uppal S, Pearlman MD, Maturen KE, Priyanka S, Shanthi S, Bueno LM, Caun DL, Comelis MT, Beguelini MR, Taboga SR, Morielle-Versute E, Siar M, Teshnehlab M. Concurrency and Computation Practice and Experience, 2026 Aug 1; 38 (15): DOI:10.1002/cpe.70892
    • Journal Article
      Management and Prevention of Histotripsy-Induced Acute Bland Portal Vein Thrombosis in Histotripsy-Treated Liver Tumors.
      Worlikar T, Caoili E, Navarro A, Loudon N, Nalla A, Khaykin VM, Hudson E, Hunold T, Parikh ND, Mendiratta-Lala M. J Vasc Interv Radiol, 2026 Jun 2; 37 (9): 108883 DOI:10.1016/j.jvir.2026.108883
      PMID: 42235819
    • Journal Article
      Vascular Injury after Histotripsy: A Case Series of Hemorrhage and Pseudoaneurysm Complications in Human Patients
      Breuer JA, Mendiratta-Lala M, Lee FT, Lalani Z, Poe L, Caoili EM, Imagawa DK, Chiang J, Raman SS, Hinshaw JL, Abi-Jaoudeh N. Journal of Vascular and Interventional Radiology, 2026 Jun 1; 37 (6): DOI:10.1016/j.jvir.2026.108576
      PMID: 41655899
    • Journal Article
      Abstract No. LBA17 Histotripsy-induced acute kidney injury following liver tumor treatment: A preliminary report of 8 cases
      Poe L, Kisting A, Mendiratta-Lala M, Abi-Jaoudeh N, Breuer J, Fidelman N, Raman S, Lee F, Lokken R, Caoili E, Shah R, Hinshaw J. Journal of Vascular and Interventional Radiology, 2026 Apr 23; 37 (5): 108716 DOI:10.1016/j.jvir.2026.108716

    Featured News & Stories

    Patient receiving histotripsy treatment with health care providers using equipment
    Great Minds, Greater Discoveries Stories

    Research Impact: Histotripsy

    In late 2023, the United States Food and Drug Administration (FDA) approved the use of sound waves to break down tumors — a technique called histotripsy — in humans for liver treatment, a new therapy developed at the University of Michigan and with support from the National Institutes of Health.
    machine beige black
    Health Lab

    Histotripsy liver tumor trial successful, early clinical adoption recommended

    The #HOPE4LIVER trials, testing the safety efficacy of histotripsy as a treatment for primary and metastatic liver tumors, met its goals for technical success and safety. An expert explains more about it in this article.